Clinical Trials Logo

Esophagitis, Reflux clinical trials

View clinical trials related to Esophagitis, Reflux.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02463643 Completed - Esophagitis, Reflux Clinical Trials

To Evaluate Efficacy and Safety of Z-215 in Erosive Esophagitis

Start date: May 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of Z-215 (10 mg, 20 mg, 40 mg) , compared with Rabeprazole Sodium 10mg in patients with erosive esophagitis of Grade A to D as defined by the LA classification grading system.

NCT ID: NCT00321737 Completed - Esophagitis, Reflux Clinical Trials

Efficacy and Safety of Dexlansoprazole MR Compared to Placebo on Maintaining Healing in Subjects With Healed Erosive Esophagitis

Start date: May 2006
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the ability of once-daily (QD) treatment with dexlansoprazole modified release (MR) 30 mg and 60 mg or placebo in maintaining healing of erosive esophagitis (EE).

NCT ID: NCT00255164 Completed - Esophagitis, Reflux Clinical Trials

Efficacy and Safety of Dexlansoprazole MR on Maintaining Healing in Subjects With Healed Erosive Esophagitis

Start date: January 2006
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the ability of once-daily (QD) treatment with Dexlansoprazole modified-release (MR) 60 mg and 90 mg and placebo in maintaining healing of erosive esophagitis (EE).

NCT ID: NCT00255151 Completed - Esophagitis, Reflux Clinical Trials

Comparison of Dexlansoprazole MR to Placebo on the Ability to Maintain Healing in Subjects With Healed Erosive Esophagitis

Start date: January 2006
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the ability of once-daily (QD) treatment with Dexlansoprazole modified-release (MR) 60 mg and 90 mg and placebo in maintaining healing of erosive esophagitis (EE).

NCT ID: NCT00251719 Completed - Esophagitis, Reflux Clinical Trials

Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis

Start date: December 2005
Phase: Phase 3
Study type: Interventional

This is a study to assess the efficacy and safety of 8 weeks of treatment with Dexlansoprazole modified release (MR)(60 mg daily and 90 mg daily) compared to Lansoprazole (30 mg daily) in healing subjects with endoscopically proven erosive esophagitis.

NCT ID: NCT00251693 Completed - Esophagitis, Reflux Clinical Trials

Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis

Start date: December 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the efficacy and safety of 8 weeks of once-daily (QD) treatment with dexlansoprazole modified release (MR) 60 mg or 90 mg or lansoprazole 30 mg in healing subjects with endoscopically proven erosive esophagitis.